Platelet-activating factor (PAF) is a glycerophospholipid known for its unusual potent vasoactive and proinflammatory activities. The present study examined whether PAF might serve as a priming factor in endotoxin-induced tumor necrosis factor-a (TNFa) synthesis, cardiovascular shock, and lung injury in anesthetized rats. Intravenous infusion of PAF (1 pmol/kg/min for 60 minutes, n =5) alone or endotoxin (0.1 ,ug/kg i.v. bolus, n =5) failed to alter blood pressure, serum TNFat and thromboxane B2, platelet and leukocyte count, and hematocrit, nor was lung histology, myeloperoxidase activity, and water content changed. In contrast, the combined administration of PAF and endotoxin markedly elevated serum TNFca
Septic shock is a complex syndrome involving multiple mediators among which platelet-activating factor (PAF) and tumor necrosis factor-a (TNFa) play a major role. Many of the manifestations of endotoxic shock, such as hypotension, hemoconcentration, thrombocytopenia, leukopenia, and death, can be produced by the systemic administration of PAF' or TNFa.2 Also, elevated serum levels of PAP and TNFa455were found in lipopolysaccharide (LPS)-injected animals, and increased TNFa activity was detected in septic patients.6 PAF antagonists7 or TNFa-neutralizing antibodies8 9 each were shown to convey significant protection in animal models of septic shock. Furthermore, enhanced release of PAF from splenic lymphocytes obtained from rats exposed to bacterial peritonitis10 and the release of TNFa by monocytes and macrophages stimulated by LPS1"12 were reported as well.
Thus, it is currently believed that LPS exerts its pathophysiological effects primarily through the production of PAF and TNFa, but the relation between these mediators is poorly understood. Several in vitro studies reported that PAF13 and TNFa14 are able to elicit production of each other from cultured macrophages. In addition, TNFa was shown to prime PAF-induced superoxide production by human neutrophils. 15 However, the nature of the interaction between PAF and TNFa in mediating endotoxin effects is virtually unknown. The only in vitro study that attempted to explore such relations demonstrated that pretreatment or posttreatment of isolated murine macrophages with a PAF antagonist inhibited TNFa production in response to endotoxin16 and that high concentrations of the PAF antagonist added to the macrophage medium simultaneously with endotoxin completely inhibited TNFa mRNA expression; however, no direct measurements of PAF were provided in that study. In in vivo studies, pretreatment with the PAF antagonist BN 50739 attenuated the LPS-induced elevation of serum TNFa and decreased TNFa-induced mortality. 17 Support of the possible linkage of PAF and TNFa in septic states was provided by Heuer et al, l8 who have demonstrated that pretreatment of mice with pharmacological doses of either Salmonella typhosa endotoxin or TNFa resulted in a synergistic increase in PAF-induced mortality. However, when administered alone at similar doses, neither TNFa nor endotoxin had any effect on animal survival. In contrast, Myers et al19 observed no beneficial effect of pretreatment or posttreatment with the PAF antagonist BN 52021 on the lethality of combined low-dose endotoxin and recombinant human TNFa, which singly had no effect in mice. However, the priming effect of PAF on TNFa release was challenged by studies showing that TNFa production by blood monocytes exposed to LPS was suppressed if monocytes were first primed by PAF20 Taken together, these data suggest that PAF[INFa interactions may play a role in the mediation of endotoxin-induced pathophysiological responses. The purpose of the present study was to investigate this hypothesis in vivo and to examine a possible priming relation of PAF on LPS-induced TNFa production, cardiovascular shock, and lung injury in vivo.
Materials and Methods

Materials
PAF (L-a-phosphatidylcholine, 13-acetyl-y-O-hexadecyl) was purchased from Sigma Chemical Co., St. Louis, and was dissolved in 0.25% essentially fatty acid-free bovine serum albumin (Sigma) in 0.9% NaCl. The stock solution was diluted in vehicle as needed, for infusion for 60 minutes in a total volume of 2 ml. Escherichia coil 0111:B4 (Sigma) was used as a fresh solution in 0.9% NaCl.
BN 50739, a potent, selective, and long-acting PAF antagonist,21 kindly provided by Dr. P. Braquet (Institut Henri Beaufour, Paris), was solubilized in 64% dimethyl sulfoxide in 0.9% NaCl to reach a concentration of 5 mg/ml.
Lyso-PAF (L-a-lysophosphatidylcholine, y-O-hexadecyl, Sigma) was prepared in the same bovine serum albumin/NaCI vehicle as PAF and was administered at 1 pmol/kg/min for 60 minutes in a total volume of 2 ml.
Animals
Male Sprague-Dawley rats weighing 303-356 g (Taconic Farms, Germantown, N.Y.) were studied.
Until surgery, all animals were housed in groups of two in standard cages and provided with food and water ad libitum in a temperature-controlled room (22°C) on a 12-hour dark/light cycle.
Primary Experimental Protocols
TNFa, thromboxane B2, hematocrit, and blood pressure responses to PAF (protocol 1). After anesthesia with pentobarbital (30 mg/kg i.p.), catheters (PE-50) were introduced into the femoral vein for drug infusion and into both femoral arteries for blood pressure measurements and blood sampling. Basal mean arterial pressure (MAP) was recorded, and a blood sample (0.5 ml, exchanged with an equivolume of 0.9% NaCl) was collected for TNFa and thromboxane B2 (TXB2) assay and for hematocrit determination. PAF at 1 (n=5), 10 (n=8), or 100 pmol/kg/ min (n=7) or PAF vehicle (control, n=5) was infused at 2 mI/hr for 60 minutes. MAP was continuously monitored for 4 hours, and blood samples (0.5 ml, exchanged with an equivolume of 0.9% NaCl) for TNFa, TXB2, and hematocrit determinations were collected at 30, 60, 120, and 240 minutes after the beginning of infusion. An additional blood sample (0.3 ml, exchanged with an equivolume of 0.9% NaCl) for TXB2 assay was collected at 10 minutes.
TNFa, TXB2, hematocrit, and MAP responses to LPS (protocol 2). The former protocol was repeated with intravenous bolus injection of endotoxin at 0.1 jig/kg replacing the PAF infusion.
TNFa, TXB2, hematocrit, and MAP responses to the combined administration of PAF and LPS (protocol 3). Protocol 2 was repeated using intravenous bolus injection of endotoxin at 0.1 ,ug/kg, followed by intravenous infusion of PAF at 1 (n=5), 10 (n=5), or 100 pmol/kg/ min (n =9) at a rate of 2 ml/min for 60 minutes.
Additional Protocols
Because preliminary studies indicated a priming effect of PAF (1 pmol/kg/min) on LPS-induced TNFa release, additional protocols were used to address the following questions: 1) Does the priming result from the action of PAF or is it an effect of lyso-PAF, a key metabolite of the action of plasma acetylhydrolases on PAF? To address this issue, serum TNFa was determined in a separate group of rats (n =4) before and 30, 60, 120, and 240 minutes after the infusion of lyso-PAF (1 pmol/kg/min for 60 minutes). An additional group (n=4) was used to determine serum TNFa response to the bolus injection of LPS (0.1 ,ug/kg) followed immediately by the infusion of lyso-PAF (1 pmol/kg/ min for 2 minutes, protocol 4); this dose of lyso-PAF was chosen based on the estimate of complete conversion of PAF to lyso-PAF. To further confirm the specificity of PAF in the priming process and to test the possibility that the priming effect of PAF is receptor-mediated, a separate group of rats (n = 5) were pretreated (30 3) Are specific temporal relations of PAF and LPS involved in the interaction that leads to the priming response? To answer this question two sets of experiments were conducted. In the first set, PAF (1 pmol/ kg/min i.v.) was infused for 60 minutes, and LPS (0.1 jig/kg) was injected as an intravenous bolus at the beginning of PAF infusion (group III, Figure 1A , n=5), at the end of PAF infusion (group IV, Figure 1A, n=5) , or 120 minutes later (group V, Figure 1A , n =5). Blood samples for TNFa assay were collected at 0.5, 1, 2, and 4 hours (protocol 8). In the second set, LPS was injected as a bolus (0.1 jig/kg) followed by PAF infusion (1 pmol/kg/min) over 5 minutes (group III, Figure  1B , n=5), 15 minutes (group II, Figure 1B, n=5) , or 60 minutes (group I, Figure 1B, n=5 ). Blood samples for TNFa assay were collected at 0.5, 1, 2, and 4 hours (protocol 9). 4) Is it possible that PAF serves as an accelerator for LPS-induced effects rather than a priming mediator for LPS pathophysiological actions? To exclude this possibility it should be demonstrated that LPS (0.1 jig/kg) would not by itself produce the changes elicited by the combined administration of PAF and LPS even at later periods of time. Therefore, an endotoxin bolus was given to a separate group of chronically instrumented rats (n=5), and MAP, hematocrit, leukocytes, platelets, and serum TNFa were determined at 8, 12, 24, and 48 hours (protocol 10). 5) Is PAF priming effect related to LPS in a dose-dependent manner? To address this question, protocols 1, 2, and 3 were repeated using LPS at 0.01 jig/kg (protocol 11, n=5). MAP, hematocrit, and TNFa levels were determined.
Pulmonary water content and myeloperoxidase activity. After anesthesia with pentobarbital (30 mg/kg i.p.), a catheter (PE-50) was introduced into the femoral vein for drug infusion. PAF at 1 pmol/kg/min (n=5) or PAF vehicle (control, n=5) was infused at 2 ml/hr for 60 minutes. Other rats were given LPS (0.1 jig/kg, n=5) as a bolus or LPS as a bolus together with PAF infusion (1 pmol/kg/min for 60 minutes, n=5). Four or 24 hours later both lungs were removed; the right one was taken for MPO assay, and the left one was used to determine pulmonary water content (in the 4-hour group only). Pulmonary histopathology. The latter protocol was repeated (n=5) with the right lung removed 4 hours after treatment and fixed while inflated with phosphate-buffered formalin (pH 7.2). The lobes were divided, and one lobe was processed for paraffin sections and stained with hematoxylin and eosin using routine methods. A second lobe was further fixed in 3% glutaraldehyde in 0.1 M phosphate buffer and processed for scanning electron microscopy. These lobes were dehydrated in ethanol incubated in hexamethydisilazane23 and dried under vacuum. After drying, each lobe was sliced into four pieces, mounted on a specimen stub, and sputter-coated with gold. The lobes were examined with a Hitachi S-570 scanning electron microscope operating at 20 kV at a working distance of less than 5 mm. for which a hamster monoclonal anti-mouse TNFa (Genzyme, Boston) was used as the capture antibody and a polyclonal rabbit anti-murine TNFa (Genzyme) was used as the detecting antibody. TNFa levels in rat samples were calculated from a standard curve generated with recombinant murine TNFa (Genzyme). INFa levels determined by ELISA correlated with levels detected by the L-929 bioassay,25 with 1 unit of activity in the bioassay corresponding to 5 pg TNFa in the ELISA. The ELISA detected levels of TNFa down to 25 pg/ml. TXB2 was determined by radioimmunoassay (sensitivity of 7.8 pg/100 1al) as previously described.26 MPO activity in the lung was assayed as described previously27 based on a modification of Bradley's method. 28 Pulmonary water content. At the end of the experimental period, the left lung was removed and immediately weighed (wet weight). Dry weight was determined after the lung was dried at 80°C for 36 hours, and the pulmonary water content was calculated by subtracting the lung dry weight from the lung wet weight.
Data Analysis
Data in text and figures are mean+SEM for the indicated number of animals. One-way analysis of variance followed by Student-Newman-Keuls test was used for statistical analysis. Because of the incomplete measurement scale of the TXB2 and TNFa assays (minimal detection level of 7.8 pg/100 ,tl and 25 pg/ml, respectively), the Kruskal-Wallis test was used for TXB2 and TNFa comparisons. A value of p<0.05 was considered significant for both tests.
Results
Hemodynamic, Hematologic, and Plasma TXB2 Responses to PAF and LPS Basal MAP (104+ 9 mm Hg), platelet (810±74x 103/ ,ul) and leukocyte count (8,090±680/,l), and hematocrit (46.3±0.9%) did not differ among the groups and are in agreement with the normal values of this species of rats.29 Basal TXB2 levels in all groups were below the minimal detecting level of the assay that was used (7.8 pg/100 ,l). This is in agreement with previous studies that used radioimmunoassay. 30, 31 PAF at 100 pmol/kg/min infused at a rate of 2 ml/hr for 60 minutes induced hypotension (Figure 2 ), hemoconcentration ( Figure 3A) , and marked elevation of plasma TXB2 (Figure 4 ). PAF at 1 or 10 pmol/kg/min; PAF vehicle, administered in a similar fashion; or endotoxin (0.1 ,g/kg) did not affect these variables (Figures 2, 3A, 4) . Also, PAF at 1 pmol/kg/ min had no effect on leukocyte and platelet count. In contrast, the bolus injection of LPS (0.1 ,g/kg) followed by PAF infusion (1 pmol/kg/min over 60 minutes) caused hypotension (p<0.01, Figure 2 ), hemoconcentration (p<0.05, Figure 3A) , leukopenia (p<0.05, Figure 3B ), thrombocytopenia (p<0.05, Figure 3C ), and elevation of plasma TXB2 (p<0.01, Figure 4 ). Desensitization to PAF effect on LPSinduced hypotension, hemoconcentration, and elevation of plasma TXB2 developed during the last 30 minutes of PAF infusion, as shown by a decrease in these responses at that time.
LPS at 0.1 ttg/kg did not affect MAP (basal, 105+ 10 mm Hg), hematocrit (basal, 45 + 1%), or platelet (basal, 792±67x 103/,ul) and leukocyte counts (basal, 8.4±0.7x 103/,ul) at 8, 12, 24 and 48 hours (protocol 10). LPS at 0.01 pg/kg did not affect MAP and hematocrit when injected alone or in combination with PAF infusion (protocol 11, Table 1 ).
TNFa Response to PAF and LPS
Basal TNFa levels were undetectable at the level of the assay sensitivity of 25 pg/ml, which agrees with previous reports in rats.4589 7 PAF at 100 or 10 pmol/kg/min for 60 minutes slightly elevated serum TNFa (162±70 pg/ml at 4 hours, p<0.05, Figure 5 Figure   6C ) since at this dose the separate infusion of PAF had no effect on serum TNFa activity. In contrast, PAF at doses of 10 ( Figure 6B ) or 100 pmol/kg/min ( Figure 6A) The specificity of PAF in the priming process was established by the following observations: 1) Pretreatment with BN 50739 completely prevented (p<0.01) the elevation of serum TNFa induced by the combined administration of PAF (100 pmol/kg/ min) and LPS (0.1 gg/kg; Figure 6A ), and 2) the infusion of lyso-PAF with or without bolus injection of LPS had no effect on serum TNFa (Figure 7 ). induced hypotension (Figure 2 ), hemoconcentration ( Figure 3A) , leukopenia ( Figure 3B ), thrombocytopenia ( Figure 3C ), elevation of serum TXB2 (Figure 4) and TNFa ( Figure 6C , Figure 8A ), lung edema ( Figure 9 ), MPO activity ( Figure 10 ), and histological changes (Figures 11-13 Figure 8B ). There was no priming effect when PAF was infused for 5 minutes only. Lung MPO, Weight, and Water Content
The wet (502+5 mg), dry (93+7 mg), and wet-dry (pulmonary water content, 409±9 mg) lung weight of the control rats did not differ statistically from the respective weights in groups of rats receiving PAF or LPS only (Figure 9 ). In contrast, the combined administration of PAF and LPS significantly elevated pulmonary wet, dry, and wet-dry weight by 18% (n=5, p<0.01) each; the wet-dry/dry ratio (4.40+0.01), however, remained unchanged.
Control animals had pulmonary MPO activity of 4.99+0.54 units/g wet lung wt. This value was not significantly affected by the separate administration of PAF or LPS (Figure 10 ), whereas bolus injection of LPS followed immediately by PAF infusion increased MPO activity by 519±43% at 4 hours (p<0.01, Figure lOA (Figure 11 ). At 24 hours after LPS and PAF were given in combination, the disease process observed at A. Figure 13A ). A few platelets and leukocytes were adherent to the A. combination ( Figure 13C ). These leukocytes were covered with numerous blebs and ruffles (in contrast to the fine microvilli in the other groups), probably the result of shortening and broadening of the microvilli, findings previously reported in activated neutrophils. 33 The above-listed histopathological changes were noticed uniformly in all lung areas and in all five rats. Interestingly, no evidence of adherent leukocytes, platelets, or fibrin was seen in the pulmonary arteries of any of the treatment groups.
Survival
All rats given PAF (1 pmol/kg/min), LPS (0.1 gg/kg), or PAF combined with LPS (at similar doses) survived the 48-hour observation period.
Discussion
The key finding of this study is that PAF and endotoxin cooperate to produce TNFce, cardiovascular derangements, and lung injury in vivo, possibly through a specific priming effect of PAF on LPSresponsive cells and organs. Our data suggest that PAF serves as a priming factor rather than an accelerator of LPS-induced pathophysiological effects since, when administered alone, LPS did not affect hemodynamic, hematologic, and biochemical variables for 48 hours after injection. In addition, it is suggested that PAF primes for LPS-induced lung injury, cardiovascular shock, and TNFa and TXB2 production and not vice versa (i.e., LPS primes for nary parenchyma. It was recently suggested that TNFa induces neutrophil-dependent pulmonary edema associated with increased vascular permeability (mediated by PAF) and pulmonary capillary pressure (mediated by TXA2 and PAF46). Taken together, these data might point to the possibility that PAF could serve as a priming factor for the development of ARDS in septic states, acting at early times when plasma endotoxin levels are still extremely low.
The main characteristics of the priming process are 1) it requires the presence of PAF in the circulation. This conclusion was drawn since the injection of LPS at 120 minutes after the termination of PAF infusion, when PAF was already cleared from the circulation (half-life of <30 seconds47), did not prime for TNFa production; 2) it necessitates PAF stimulation over a minimal period of 5 to 15 minutes (since priming was demonstrated when PAF was infused for 15 minutes but not when infused for 5 minutes); and 3) it is subjected to desensitization (there was no priming after the injection of LPS at the end of PAF infusion, when PAF is still present in the circulation).
The pathophysiological pathways by which the priming effect of PAF facilitates LPS-induced lung injury and the mechanism of the priming effect of PAF on TNFa production in response to LPS are currently unknown. It is possible that PAF induces the production of TNFa in response to LPS or, alternatively, that PAF inhibits a TNFa-degrading protease(s). However, the latter possibility is unlikely, because LPS on its own did not produce TNFa. Nevertheless, several mechanisms were suggested for PAF/TNFa amplification processes in models other than endotoxin shock. For example, Braquet et a115 suggested that the amplification of superoxide production induced by PAF To maintain an adequate stimulus for TNFa production, PAF was infused intravenously for 60 minutes. The infusion of PAF caused hypotension, hemoconcentration, and elevation of plasma TXB2, all well-known effects of PAF when injected as a bolus (for review, see Reference 1) . However, in contrast to the administration of PAF as an intravenous bolus,348 desensitization was developed during the second half of the infusion period. These data are in agreement with those reported by Ezra et 
